Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Patent
1997-02-07
1998-11-03
Saunders, David
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
424 851, 424 852, 424 855, 4242771, 4242781, 435372, 435384, 435385, 435386, 530350, A61K 3900, A61K 4505, C12N 508, C07K 14435
Patent
active
058304649
ABSTRACT:
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule in combination with administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex when administered intradermally are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96. In another embodiment, the effective amounts of the complex when administered subcutaneously are in the range of 10 to 600 micrograms for complexes comprising hsp70, 50 to 5000 micrograms for hsp90, and 10 to 600 micrograms for gp96.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 5188964 (1993-02-01), McGuire et al.
patent: 5232833 (1993-08-01), Sanders et al.
patent: 5348945 (1994-09-01), Berberian et al.
Aldovini et al. (1992) "The New Vaccines", Technology Review pp. 24-31.
Barrios et al. (1992) "Mycobacterial heat-shock proteins as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines that can circumvent the need for adjuvants and Bacillus Calmette Guerin priming", Eur. J. Immunol. 22:1365-1372.
Barrios et al. (1994) "Specifcity of antibodies induced after immunization of mice with the mycobacterial heat shock proteins of 65 kD", Clin. Exp. Immunol. 98:224-228.
Barrios et al. (1994) "Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and DnaK proteins requires cross-linking with antigen", Clin. Exp. Immunol. 98:229-233.
Bartholeyns and Lopez (1994) "Immune contol of neoplasia transfer of macrophages: potentiality for antigen presentation and gene transfer", Anticancer Research 14:2673-2676.
Basombrio (1970) "Search for common antigenicities among twenty-five sarcomas induced by methylcholanthrene", The Institute for Cancer Research 30:2458-2462.
Blachere et al. (Mar. 1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells/antigens", J. Cell Biochem Suppl 17D:124 (Abstract NZ 502).
Blachere et al. (1993) "Heat Shock Protein Vaccines Against Cancer," Journal of Immunotherapy 14:352-356.
Blachere and Srivastava (1993) "Immunization with GP96 heat shock proteins isolated from tumors or influenza virus infected cells elicits MHC-restricted, antigen-specific cytotoxic T lymphocytes against the corresponding cells," J. Cellular Biochem. Keystone Symposia NZ502, p. 124.
Boon (1992) "Toward a genetic analysis of tumor rejection antigens", Advances in Cancer Research 58:177-210.
Chou et al. (1988) "adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors", J. Immunology 141:1775-1781.
Cohen (1993) "Cancer Vaccines Get A Shot In the Arm", Science 262:841:843.
Craig (1993) "Chaperones: Helpers Along the Pathways to Protein Folding", Science 260:1902-1904.
Elliott et al. (1990) "Naturally Processed Peptides", Nature 348:195-197.
Falk et al. (1991) "Allele-specific Motifs Revealed by Sequencing of Self-peptides Eluted from MHC Molecules", Nature 351:290-296.
Falk et al. (1990) "Cellular Peptide Composition Governed by Major Histocompatibility Complex Class I Molecules", Nature 348:248-251.
Fedweg and Srivastava (1993) "Evidence for biochemical heterogeneity of gp96 heat shock protein/tumor rejection antigen", Mount Sinai School fo Medicine NZ 206, p. 108.
Flynn et al. (1989) "Peptide binding and release by proteins implicated as catalysts of protein assembly", Science 245:385-390.
Flynn et al. (1991) "Peptide-binding Specificity of the Molecular Chaperone BiP", Nature 353:726-730.
Franklin (1993) "Making vaccines fit the cancer", New Scientist 140:17.
Gething et al. (1992) "Protein Folding in the Cell", Nature 355:33-45.
Globerson and Feldman (1964) "Antigenic specificity of 32(6):1229-1242.
Grabbe et al. (1991) "Tumor antigen presentation by mature epidermal cells", J. Immunology 146:3656-3661.
Jakob et al. (1993) "Small Heat Shock Proteins Are Molecular Chaperones", J. Biol. Chem. 268:1517-1520.
Jardetzky et al. (1991) "Identification of Self Peptides Bound to Purified HLA-B27", Nature 353:326-329.
Lakey et al (1987) "Identification of a peptide binding protein that plays a role in antigen presentation", Proc. Natl. Acad. Sci USA 84:1659-1663.
Lanzavecchia (1993) "Identifying Strategies for Immune Intervention", Science 260:937-944.
Levinson et al. (1979) "Metal Binding Drugs Induce Synthesis of Four Proteins in Normal Cells", Biol Trace Element Research 1:15-23.
Levy (1991) "ATP is Required for In Vitro Assembly of MHC Class I Antigens but Not for Transfer of Peptides across the ER Membrane", Cell 67:265-274.
Li and Srivastav (1993) "Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation", EMBO J. 12(8):3143-3151.
Lindquist and Craig (1988) "The heat-shock proteins", Ann. Rev. Genet. 22:631-677.
Luescher et al. (1991) "Specific Binding of Antigenic Peptides to Cell-associated MHC Clas I Molecules", Nature 351:72-77.
Lukacs et al. (1993) "Tumor cells transfected with a bacterial heat-shock gene lose tumorigencity and induce protection against tumors", J. Exp. Med. 178:343-348.
Lussow et al. (1991) "Mycobacterial heat-shock proteins as carrier molecules", Eur. J. Immunol. 21:2297-2302.
Madden et al. (1991) "The Structure of HLA-B27 Reveals Nonamer Self-peptides Bound in an Extended Conformation", Nature 353:321-325.
Maki et al. (1993) "Mapping of the Genes for Human Endoplasmic Reticular Heat Shock Protein gp96/grp94", Somatic Cell Mol. Genetics 19(1):73-81.
Maki et al. (1990) "Human homologue of murine tumor rejection antigen gp96: 5'-Regulatory and coding regions and relationship to stress-induced proteins", Proc. Natl. Acad. Sci. USA 87:5658-5663.
Martin et al. (1986) "Role of Murine Tumor Models in Cancer Treatment Research", Cancer Research 46:2189-2192.
McCall et al. (1989) "Biotherapy: A New Dimension in Cancer Treatment", Biotechnology 7:231-240.
Melnick (1985) "Virus Vaccines: An Overview", Proceedings of the First Annual Southwest Foundation for Biomedical Research International Symposium, Houston, Texas, 8-10 Nov. 1984, American Society for Microbiology pp. 1-13.
Mule et al. (1984) "Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2", Science 225:1487-1489.
Nelson et al. (1992) "The Translation Machinery and 70 kd Heat Shock Protein Cooperate in Protein Synthesis", Cell 71:97-105.
Nieland et al., (1996) "Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94", Proc. Natl. Acad. Sci. USA 93:6135-6139.
Palladino et al. (1987) "Expression of shared tumor-specific antigen by two chemically induced BALB/c sarcomas", Cancer Research 47:5074-5079.
Prehn and Main (1957) "Immunity to methylcholanthrene-induced sarcomas", Journal of the National Cancer Institute 18(6):769-778.
Ramsey and Rank (1991) "Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines", Infection and Immunity 59:925-931.
Rosenberg et al. (1988) "Use of Tumor Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastic Melanoma", New Engla
Fordham University
Saunders David
VanderVegt F. Pierre
LandOfFree
Compositions and methods for the treatment and growth inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the treatment and growth inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the treatment and growth inhibition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-686702